One Step Derivation of Cardiomyocytes and Mesenchymal Stem Cells From Human Pluripotent Stem Cells

Wei, Heming; Tan, Grace; Manasi, Manasi; Yong, Pearly; Koh, Cai Hong; Ooi, Ting Huay; Lim, Sze Yun; Wong, Philip; Shen, Gan; Shim, Winston

doi:10.1016/s0735-1097(12)61392-8

Cited by 19 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, iPSC-MSCs have a greater expansion capacity, maintaining differentiation potential and normal karyotypes for 120 doublings, while BM-MSCs get senescent after 20 doublings [11]. Second, BM-MSCs may present reduced survival and differentiation ability when isolated from aged subject or patients with ageing-related disorders [12][13][14][15]. iPSC-MSCs may overcome the ageing-associated impairment of BM-MSCs, which may be important in COPD wherein the prevalence, morbidity and mortality are related to age [16][17][18].…”

Section: Discussionmentioning

confidence: 99%

“…Induced pluripotent stem cells can differentiate into MSCs through an induced-differentiation protocol, providing a new source of MSCs (iPSC-MSCs) [11]. Compared with BM-MSCs, iPSC-MSCs have a much higher ability of proliferation without loss of differentiation potential [11] and hold potential to overcome ageing-associated impairment [12][13][14][15]. This may be particularly important for COPD as the prevalence, morbidity and mortality of the disease are highly correlated with age [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

iPSC‐derived mesenchymal stem cells exert SCF‐dependent recovery of cigarette smoke‐induced apoptosis/proliferation imbalance in airway cells

Zhang

Liang

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have emerged as a potential cell‐based therapy for pulmonary emphysema in animal models. Our previous study demonstrated that human induced pluripotent stem cell–derived MSCs (iPSC‐MSCs) were superior over bone marrow–derived MSCs (BM‐MSCs) in attenuating cigarette smoke (CS)‐induced airspace enlargement possibly through mitochondrial transfer. This study further investigated the effects of iPSC‐MSCs on inflammation, apoptosis, and proliferation in a CS‐exposed rat model and examined the effects of the secreted paracrine factor from MSCs as another possible mechanism in an in vitro model of bronchial epithelial cells. Rats were exposed to 4% CS for 1 hr daily for 56 days. At days 29 and 43, human iPSC‐MSCs or BM‐MSCs were administered intravenously. We observed significant attenuation of CS‐induced elevation of circulating 8‐isoprostane and cytokine‐induced neutrophil chemoattractant‐1 after iPSC‐MSC treatment. In line, a superior capacity of iPSC‐MSCs was also observed in ameliorating CS‐induced infiltration of macrophages and neutrophils and apoptosis/proliferation imbalance in lung sections over BM‐MSCs. In support, the conditioned medium (CdM) from iPSC‐MSCs ameliorated CS medium‐induced apoptosis/proliferation imbalance of bronchial epithelial cells in vitro. Conditioned medium from iPSC‐MSCs contained higher level of stem cell factor (SCF) than that from BM‐MSCs. Deprivation of SCF from iPSC‐MSC‐derived CdM led to a reduction in anti‐apoptotic and pro‐proliferative capacity. Taken together, our data suggest that iPSC‐MSCs may possess anti‐apoptotic/pro‐proliferative capacity in the in vivo and in vitro models of CS‐induced airway cell injury partly through paracrine secretion of SCF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

iPSC‐derived mesenchymal stem cells exert SCF‐dependent recovery of cigarette smoke‐induced apoptosis/proliferation imbalance in airway cells

Zhang

Liang

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…One solution to this problem of uniform cell sourcing is the use of MSC derived from induced pluripotent stem cells (iPSC). A number of studies have determined that iPSC‐derived MSC (iMSC) closely resemble conventional bone marrow or adipose‐tissue derived MSC in terms of both phenotype and function . The ability of iMSC to suppress inflammation in vivo has also been demonstrated in mouse models, including allergic airway disease .…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model

Soontararak

Chow

Johnson

et al. 2018

Stem Cells Translational Medicine

151

116

View full text Add to dashboard Cite

Cellular therapy with allogeneic or autologous mesenchymal stem cells (MSC) has emerged as a promising new therapeutic strategy for managing inflammatory bowel disease (IBD). However, MSC therapy ideally requires a convenient and relatively homogenous cell source (typically bone marrow or adipose tissues) and the ability to generate cells with stable phenotype and function. An alternative means of generating allogeneic MSC is to derive them from induced pluripotent stem cells (iPSC), which could in theory provide an indefinite supply of MSC with well‐defined phenotype and function. Therefore, we compared the effectiveness of iPSC‐derived MSC (iMSC) and adipose‐derived MSC (adMSC) in a mouse model of IBD (dextran sodium sulfate‐induced colitis), and investigated mechanisms of intestinal protection. We found that iMSC were equivalent to adMSC in terms of significantly improving clinical abnormalities in treated mice and reducing lesion scores and inflammation in the gut. Administration of iMSC also stimulated significant intestinal epithelial cell proliferation, increased in the numbers of Lgr5+ intestinal stem cells, and increased intestinal angiogenesis. In addition, the microbiome alterations present in mice with colitis were partially restored to resemble those of healthy mice following treatment with iMSC or adMSC. Thus, iMSC administration improved overall intestinal health and healing with equivalent potency to treatment with adMSC. This therefore is the first report of the effectiveness of iMSC in the treatment of IBD, along with a description of unique mechanisms of action with respect to intestinal healing and microbiome restoration. stem cells translational medicine 2018;7:456–467

show abstract

“…Recent data suggest that iMSCs are emerging as a strong contender for the new sources of MSCs that could be suitable to replace the adult MSCs. Particularly, of late many studies have reported successful derivation of functional MSCs from iPSCs (iMSCs) [33,36,50,58,[89][90][91][92]. The iMSCs are a novel class of stem cells that augments effective and reliable regeneration than contemporary methods.…”

Section: Establishment Of Reliable and Standardized Source Of Functiomentioning

confidence: 99%

“…Tracking of transplanted iMSCs divulged, iMSCs could engraft and survive for more than 5 weeks following transplantation [58]. Wei et al indicated human iMSCs could continuously proliferate for more than 32 passages without undergoing cellular senescence and displayed superior wound healing and pro-angiogenic properties [92]. The iMSCs derived on a synthetic polymeric coating; PMEDSAH resulted in novel bone formation when transplanted into the mice with calvarial defects [91].…”

Section: Therapeutic Applications Of Imscsmentioning

confidence: 99%

hiPSC‐derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine

Sabapathy

Kumar

2016

J Cellular Molecular Medi

102

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are being assessed for ameliorating the severity of graft‐versus‐host disease, autoimmune conditions, musculoskeletal injuries and cardiovascular diseases. While most of these clinical therapeutic applications require substantial cell quantities, the number of MSCs that can be obtained initially from a single donor remains limited. The utility of MSCs derived from human‐induced pluripotent stem cells (hiPSCs) has been shown in recent pre‐clinical studies. Since adult MSCs have limited capability regarding proliferation, the quantum of bioactive factor secretion and immunomodulation ability may be constrained. Hence, the alternate source of MSCs is being considered to replace the commonly used adult tissue‐derived MSCs. The MSCs have been obtained from various adult and foetal tissues. The hiPSC‐derived MSCs (iMSCs) are transpiring as an attractive source of MSCs because during reprogramming process, cells undergo rejuvination, exhibiting better cellular vitality such as survival, proliferation and differentiations potentials. The autologous iMSCs could be considered as an inexhaustible source of MSCs that could be used to meet the unmet clinical needs. Human‐induced PSC‐derived MSCs are reported to be superior when compared to the adult MSCs regarding cell proliferation, immunomodulation, cytokines profiles, microenvironment modulating exosomes and bioactive paracrine factors secretion. Strategies such as derivation and propagation of iMSCs in chemically defined culture conditions and use of footprint‐free safer reprogramming strategies have contributed towards the development of clinically relevant cell types. In this review, the role of iPSC‐derived mesenchymal stromal cells (iMSCs) as an alternate source of therapeutically active MSCs has been described. Additionally, we also describe the role of iMSCs in regenerative medical applications, the necessary strategies, and the regulatory policies that have to be enforced to render iMSC's effectiveness in translational medicine.

show abstract

One Step Derivation of Cardiomyocytes and Mesenchymal Stem Cells From Human Pluripotent Stem Cells

Cited by 19 publications

References 0 publications

iPSC‐derived mesenchymal stem cells exert SCF‐dependent recovery of cigarette smoke‐induced apoptosis/proliferation imbalance in airway cells

iPSC‐derived mesenchymal stem cells exert SCF‐dependent recovery of cigarette smoke‐induced apoptosis/proliferation imbalance in airway cells

Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model

hiPSC‐derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine

Contact Info

Product

Resources

About